Pfizer on Tuesday forecast 2026 profit below Wall Street estimates as it expects a drop in sales of its COVID products and a ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Novo Nordisk can end the horror year of 2025 on a positive note. The EMA has issued a positive opinion on a higher Wegovy ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...

Medications like Ozempic mimic a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which helps regulate blood sugar and appetite. GLP-1 is primarily secreted from the intestines, ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...